Overcoming the Challenge;In VivoEfficacy of Miltefosine for Chronic Cutaneous Leishmaniasis

Basit Öğe Kaydı
dc.contributor.authorTunali, Varol
dc.contributor.authorHarman, Mehmet
dc.contributor.authorcavus, Ibrahim
dc.contributor.authorGunduz, Cumhur
dc.contributor.authorOzbilgin, Ahmet
dc.contributor.authorTurgay, Nevin
dc.date.accessioned2024-04-24T16:02:31Z
dc.date.available2024-04-24T16:02:31Z
dc.date.issued2021
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground Cutaneous Leishmaniasis (CL) is the most common form of leishmaniasis. CL can be divided into two major groups: acute CL (ACL) and chronic CL (CCL). The aim of this study is to compare the efficacy of miltefosin and pentavalent antimony compoundsin vivowith the CCL patient samples. Materials Three study groups were formed, each consisting of five male Mus musculus (Balb/C) mice. In this model, promastigotes from the culture of a CCL patient were utilized. 100 mu LL. tropicapromastigote suspension with a density of 10(8)promastigotes/ml were injected into the hint-right footpad of each experimental animal intradermally. Footpads of the mice were measured every two weeks until 24th week. From the 13th week, miltefosin 50 mg/kg/day was administered orally using gavage for 21 days, Meglumin antimoniate (MA) was administered by intramuscular (IM) injection daily for 21 days at 50 mg/kg/day and saline was administered IM for 21 days for the miltefosine, MA and control group, respectively. Results The footpad measurements of the miltefosine group were lower than the control group statistically. Between the MA group and the miltefosine group and MA group and the control group, there was no statistically significant difference. Giemsa stained slides revealed amastigotes in one, two and all of the slides for the miltefosine, MA and control group, respectively. Molecular tests were performed with the Rotor-Gene device andL. tropicaconsistent peaks were obtained in one of the miltefosine group, four in the MA group and all mice in the control group. Conclusions Demonstration of both clinical and laboratory improvement in four of the five experimental animals provides strong evidence that miltefosine is an effective drug in the treatment of CCL. In the literature, no clinical or laboratory studies using miltefosine have been performed with CCL patients only.en_US
dc.description.sponsorshipResearch Funds of Ege University [17-TIP-017]en_US
dc.description.sponsorshipThis project was supported by Research Funds of Ege University with the Project no: 17-TIP-017.en_US
dc.identifier.doi10.1007/s11686-020-00285-0
dc.identifier.endpage360en_US
dc.identifier.issn1230-2821
dc.identifier.issn1896-1851
dc.identifier.issue2en_US
dc.identifier.pmid32996014
dc.identifier.scopus2-s2.0-85091731943
dc.identifier.scopusqualityQ3
dc.identifier.startpage354en_US
dc.identifier.urihttps://doi.org/10.1007/s11686-020-00285-0
dc.identifier.urihttps://hdl.handle.net/11468/14822
dc.identifier.volume66en_US
dc.identifier.wosWOS:000573738000003
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringer Int Publ Agen_US
dc.relation.ispartofActa Parasitologica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCutaneous Leishmaniasisen_US
dc.subjectDrug Resistanceen_US
dc.subjectAnimal Modelen_US
dc.subjectTurkeyen_US
dc.titleOvercoming the Challenge;In VivoEfficacy of Miltefosine for Chronic Cutaneous Leishmaniasisen_US
dc.titleOvercoming the Challenge;In VivoEfficacy of Miltefosine for Chronic Cutaneous Leishmaniasis
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu